KMKunihiro Matsushita

Kunihiro Matsushita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kunihiro Matsushita has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:

  • Josef Coresh

    Johns Hopkins University, Baltimore, Maryland, USA; Optimal Aging Institute, New York University Grossman School of Medicine, New York, New York, USA; Departments of Population Health and Medicine, New York University Grossman School of Medicine, New York, New York, USA

    71 shared publications
  • Josef Coresh

    Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, USA

    43 shared publications
  • Shoshana H. Ballew

    Optimal Aging Institute, Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA

    34 shared publications
  • Yingying Sang

    Optimal Aging Institute, Department of Population Health New York University Grossman School of Medicine New York NY USA

    32 shared publications
  • Elizabeth Selvin

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland

    28 shared publications
  • Yejin Mok

    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

    26 shared publications

Latest Publications

  • Proteomics and Risk of Incident Ischemic Stroke: Meta-Analysis of the ARIC Study and CHS

    by Wendy Wang, Yinxiang Wu, Rizwan Kalani, Ting Ye, Traci M. Bartz, Michael J. Zhang, James S. Pankow, Kamakshi Lakshminarayan, Alvaro Alonso, Pamela L. Lutsey, et al.

    BACKGROUND: Ischemic stroke preventive therapies have been slow to emerge due to a limited understanding of the underlying molecular mechanisms. We aimed to discover new protein risk factors that are potential etiologic factors and may be candidates for therapeutic intervention. METHODS: We included ARIC study (Atherosclerosis Risk in Communities) and CHS (Cardiovascular Health Study) participants without prevalent stroke at the time of proteomic profiling (1990–1992 in ARIC and 1992–1993 in CHS). Relative concentrations of proteins in blood were assessed with aptamers (n=4954). Ischemic stroke events were adjudicated through 2019 in ARIC and 2015 in CHS. Study-specific Cox regression adjusting for ischemic stroke risk factors was used to estimate associations between proteins and incident ischemic stroke. Study-specific estimates were combined using fixed-effects meta-analysis. Replication was conducted in 2 independent cohorts (AGES-Reykjavik, UK Biobank). Proteins with a false discovery rate q value P −5 ), of which 26 are novel. In 2 independent cohorts, 37 (84%) associations were directionally concordant, and 26 (59%) met criteria for replication. Mendelian randomization analyses suggested MMP12 (matrix metallopeptidase-12) and CNTN1 (contactin-1) may be causally related to ischemic stroke risk. In multivariable Mendelian randomization analyses, higher MMP12 levels had a direct protective effect on ischemic stroke risk, while CNTN1 had a direct harmful effect. CONCLUSIONS: This proteomic and genomic investigation of ischemic stroke identified novel risk biomarkers and 2 potential etiologic CNTN1 factors that are regulated in response to atherosclerosis and obesity. If future studies confirm our findings, these results may have implications for the development of new preventive therapies.

  • Associations of Mild or Trace Valvular Abnormalities With Cardiac Remodeling in Older Adults: The ARIC Study

    by Yumin Gao, Jonathan Rubin, Susan Cheng, Lena Mathews, Ajay J. Kirtane, Ron C. Hoogeveen, Christie M. Ballantyne, Elizabeth Selvin, Martin B. Leon, Josef Coresh, et al.

    Background: The impact of mild/trace valvular abnormalities on cardiac remodeling is not well understood, despite their association with poor cardiovascular outcomes. Methods: Using data from 4684 participants in the ARIC (Atherosclerosis Risk in Communities) Study (2011–2013), aged 66 to 90 years, we examined cross‐sectional associations of mild/trace valvular abnormalities (aortic stenosis, aortic regurgitation, and mitral regurgitation) with cardiac parameters using multivariable linear regression models. Cardiac parameters included cardiac structure (eg, left ventricular mass index), systolic function (eg, ejection fraction), diastolic function, and biomarkers (eg, high‐sensitivity cardiac troponin T). Results: The prevalence was 4.3% for mild aortic stenosis, 10.9% for mild/trace aortic regurgitation, and 44.7% for mild/trace mitral regurgitation. Mitral regurgitation showed the most consistent associations with cardiac measures (left ventricular mass index 5.48 g/m 2 [95% CI, 4.38–6.57 g/m 2 ]; ejection fraction –1.92% [95% CI, −2.29% to −1.54%]; high‐sensitivity cardiac troponin T 0.08 log ng/L [95% CI, 0.05–0.12 log ng/L]). Aortic stenosis was associated with impaired ventricular filling (Ratio of early transmitral flow velocity to early diastolic mitral annular velocity (E/e’) lateral ratio 2.00 [95% CI, 1.48–2.53]) and elevated biomarkers (high‐sensitivity cardiac troponin T 0.17 ng/L [95% CI, 0.09–0.25 ng/L]), whereas aortic regurgitation was associated with worsened cardiac structure (left ventricular mass index 3.52 [95% CI, 1.76–5.28] g/m 2 ) and systolic dysfunction (ejection fraction −1.54% [95% CI, −2.14% to −0.94%]). A dose–response relationship was also observed between the number of total abnormalities and all cardiac parameters examined. Conclusions: Mild/trace mitral regurgitation was most consistently associated with all cardiac parameters examined. Aortic stenosis was associated with elevated E/e’ lateral ratio and high‐sensitivity cardiac troponin T, whereas aortic regurgitation was associated with worsening in cardiac structure and ejection fraction. Our study supports the possibility of pathophysiological contributions of these mild/trace valvular abnormalities.

  • Metabolites Associated With Long-Term Risk of Peripheral Artery Disease: The ARIC Study

    by Eyram Cyril Bansah, Xiao Hu, Shoshana H. Ballew, Morgan E. Grams, Vijay Nambi, Elizabeth Selvin, Josef Coresh, Eric Boerwinkle, Bing Yu, Kunihiro Matsushita

    BACKGROUND: Lower extremity peripheral artery disease (PAD) is a major contributor to cardiovascular morbidity and mortality; however, the metabolic pathways underlying disease development and progression are poorly understood. METHODS: We conducted a prospective cohort study of 3759 participants from the ARIC study (Atherosclerosis Risk in Communities; mean age, 53.5 years; 60% women; 62% Black participants) with untargeted metabolomic profiling at baseline (1987–1989). Incident PAD (458 cases) and its severe form with rest pain or tissue loss, critical limb ischemia (CLI; 135 cases), were identified through hospitalization codes over a median follow-up of 27 years. We used Cox regression with adjustment for traditional risk factors and accounted for multiple testing using a false discovery rate correction at a threshold of 0.05. Risk prediction improvement was evaluated using Harrell C statistics and the net reclassification improvement. RESULTS: Thirteen metabolites were significantly associated with incident PAD and primarily reflected dysregulated glycemic control, impaired redox balance, and altered lipid remodeling (eg, higher levels of mannose and lower levels of 1,5-anhydroglucitol, gamma-glutamyl dipeptides, and lysophospholipids). For CLI, 18 metabolites were identified, 11 of which were unique to CLI and reflected intensified oxidative and bioenergetic stress (eg, homocitrulline, arabonate, and 1-linoleoylglycerol). Metabolites significantly improved risk prediction for PAD beyond traditional risk factors (∆C statistic, 0.017 [95% CI, 0.008–0.025] from a base C statistic of 0.770; net reclassification improvement, 0.053 [95% CI, 0.018–0.083]) and particularly CLI (∆C statistic, 0.041 [95% CI, 0.018–0.064] from a base C statistic of 0.823; net reclassification improvement, 0.176 [95% CI, 0.085–0.268]). CONCLUSIONS: Distinct metabolomic profiles were associated with incident PAD and CLI years before clinical onset, highlighting dysregulated glycemic control, impaired redox balance, and altered lipid remodeling as key underlying pathways. These findings suggest that circulating metabolites may serve as early indicators of metabolic health relevant to PAD risk identification and progression to advanced disease.

  • Open Access

    General and Exertional Fatigue, Quality of Life, and Risk of Incident Clinical Heart Failure in Those With Pre‐heart Failure in the ARIC Study

    by Noelle V. Pavlovic, Martha Abshire Saylor, Cheryl R. Himmelfarb, Christopher S. Lee, Amil M. Shah, Patricia P. Chang, Sabra Lewsey, Yvonne Commodore‐Mensah, Kunihiro Matsushita, Chiadi E. Ndumele

    Background: General and exertional fatigue are associated with worse outcomes in clinical heart failure (HF). Little is known about their prognostic importance in stage B HF. Methods: We included 2972 individuals at visit 5 (2011–2013) of the ARIC (Atherosclerosis Risk in Communities) study without clinical HF but with echocardiographic or biomarker evidence for stage B HF. Using general and exertional fatigue scale scores, individuals were categorized as low/no fatigue, high general fatigue only, high exertional fatigue only, or high general and high exertional fatigue. We determined their associations with quality of life and incident HF events using adjusted linear and Cox regression, respectively. Results: Participants were 60% female, 18% Black, with a mean age of 76 years. Compared with low/no fatigue, all fatigue categories were associated with lower quality of life, with high general and high exertional fatigue having the lowest scores (physical: β=−11.48 [95% CI, −12.80 to −10.17]; mental: β=−5.97 [95% CI, −7.03 to −4.92]). There were 338 incident HF events over a median of 8.4 years. Compared with low/no fatigue, increased incident HF overall was found for high exertional fatigue only (hazard ratio [HR], 1.86 [95% CI, 1.39–2.49]) and high general and high exertional fatigue (HR, 2.16 [95% CI, 1.46–3.20]) but not general fatigue only (HR, 1.42 [95% CI, 0.99–2.04]). All 3 categories were independently associated with increased risk of incident HF with preserved ejection fraction but not with HF with reduced ejection fraction. Conclusions: General and exertional fatigue demonstrate prognostic importance in pre‐HF and appear to be linked to underrecognized poor quality of life before the onset of clinical HF.

  • Association of Pulmonary Vascular Remodeling With Cardiac Structure and Function, Pulmonary Pressure, and Heart Failure in Late Life: The Atherosclerosis Risk in Communities (ARIC) Study

    by Aditya Dewanjee, Victoria Lamberson, Yimin Yang, Fernando R. Giugni, Brian L. Claggett, Kunihiro Matsushita, Michael J. Blaha, George Washko, Rubén San José Estépar, Pietro Nardelli, et al.

    BACKGROUND: Aging is associated with increases in pulmonary pressure related to concomitant age-associated left ventricular remodeling, diastolic dysfunction, and declines in pulmonary function. Little is known regarding morphological changes in the pulmonary arterial vasculature underlying these associations. Our aim was to determine the associations between pulmonary vascular arterial remodeling, reflected in distal pruning and proximal dilation, and cardiac structure and function, pulmonary pressure, and functional outcomes. METHODS: Among 2275 participants in the community-based Atherosclerosis Risk in Communities study (ARIC) who underwent echocardiography and noncontrast cardiac computed tomography at study visit 7 (2018–2019), we quantified the fraction of total pulmonary vascular area comprised of arterial vessels with cross-sectional area 10 mm 2 (aBVg10/aTBV) using a validated image processing approach. We assessed the associations of aBV5/aTBV and aBVg10/aTBV with echocardiographic measures of cardiac structure and function and pulmonary artery systolic pressure using multivariable linear regression models adjusted for demographics and cardiovascular risk factors. We also evaluated associations of pulmonary vascular arterial remodeling metrics with circulating NT-proBNP (N-terminal pro–B-type natriuretic peptide), self-reported dyspnea, and incident heart failure. RESULTS: Mean age was 80±4 years, 61% were women, 22% reported Black race, and mean left ventricular ejection fraction was 64±7%. Mean aBV5/aTBV was 0.30±0.08, and aBVg10/aTBV was 0.45±0.09. Lower aBV5/aTBV, reflecting greater distal pruning, and higher aBVg10/aTBV, reflecting greater proximal dilation, were both associated with greater left ventricular remodeling, worse diastolic function, and worse systolic function. Lower aBV5/aTBV and higher aBVg10/aTBV demonstrated nonlinear associations with greater pulmonary artery systolic pressure. Both lower aBV5/aTBV and higher aBVg10/aTBV were associated with higher circulating NT-proBNP and greater odds of moderate to severe dyspnea. Higher aBVg10/aTBV, in particular, was associated with greater risk of incident heart failure over a 4-year follow-up with a hazard ratio of 1.25 (95% CI, 1.03–1.51) per one SD in aBVg10/TBV. CONCLUSIONS: Among older adults, pulmonary vascular arterial remodeling is associated with greater left ventricular remodeling, worse diastolic and systolic dysfunction, greater pulmonary artery systolic pressure, greater odds of significant dyspnea, and greater risk of heart failure development. Our findings clarify the morphologic changes in the pulmonary vasculature that link cardiac dysfunction to higher pulmonary pressure in late life and may appear before symptomatology.


  • Open Access

    Reply

    by Jieun Lee, Thanh-Huyen T. Vu, Kunihiro Matsushita

  • Racial and Ethnic Differences in Predicted Cardiovascular Disease Risk Using the PREVENT Equations in the US Population

    by Sadiya S. Khan, Xiaoning Huang, Josef Coresh, Nilay S. Shah, Donald M. Lloyd-Jones, Justin B. Echouffo-Tcheugui, Kunihiro Matsushita, Chiadi E. Ndumele


  • Open Access

    Comparison of different long-term cardiovascular disease risk prediction horizons to guide preventive drug treatment in apparently healthy individuals

    by Stella Bijkerk, Janet M Kist, Lisa Pennells, Yvonne T van der Schouw, Kunihiro Matsushita, Mattijs E Numans, Emanuele Di Angelantonio, Tamar I de Vries, Ewout W Steyerberg, Jannick A N Dorresteijn, et al.

    Aims: Guideline-recommended long-term cardiovascular disease (CVD) risk prediction models use varying time horizons. This study compared which risk horizon (risk until ages 80 or 95 years, or 30-year risk) most effectively guides preventive treatment in apparently healthy individuals. Methods and results: CVD risks for all horizon were estimated using the LIFE-CVD2 model in individuals aged 35–69 years without CVD or diabetes from the Dutch ELAN registry (2007–2024; n = 364 003) and the EPIC-InterAct subcohort (1992–1998; n = 8813). Individuals in the top risk decile were compared across time horizons. Simulating blood pressure- and lipid-lowering therapy, the impact of using either time horizon was assessed by the expected gain in CVD-free life years and lifetime CVD events prevented. Individuals identified by 30-year risk were predominantly older and largely overlapped with 10-year risk (46%). In contrast, risk until ages 80 and 95 years showed less overlap with 10-year risk (18% and 20%, respectively) and identified more young men in the highest risk decile. Treatment guided by risk until ages 80 and 95 years yielded a median gain of 2.6 [IQR 2.2–2.9] CVD-free life years per person treated, with prevention of 4434 and 4658 CVD events, respectively, compared with 1.8 [IQR 1.4–1.9] years and 4215 events for 30-year risk. A hybrid strategy combining 10-year risk with risk until age 80 years yielded a median gain of 2.5 [IQR 2.1–3.0] CVD-free life years. Conclusion: Long-term CVD risk estimation until age 80 years offers a pragmatic approach to identify younger high-risk individuals not captured by 10-year risk who may benefit from preventive treatment.


  • Top Cited Papers

    Cardiovascular–Kidney–Metabolic Syndrome Stages, Echocardiographic Characteristics, and Heart Failure Risk: The Atherosclerosis Risk in Communities Study

    by Mats C. Højbjerg Lassen, John W. Ostrominski, Brian L. Claggett, Chiadi E. Ndumele, Tor Biering-Sørensen, Kunihiro Matsushita, Elizabeth Selvin, Josef Coresh, Amil Shah, Scott D. Solomon, et al.

    BACKGROUND: Suboptimal cardiovascular–kidney–metabolic (CKM) health is highly prevalent in the United States, especially among older adults, but whether the CKM syndrome staging framework is predictive of incident heart failure (HF) in this population remains uncertain. METHODS: Participants from the ARIC Study (Atherosclerosis Risk in Communities; visit 5, 2011–2013) who underwent echocardiography were categorized according to the American Heart Association CKM syndrome staging framework, which is based on excess or dysfunctional adiposity, metabolic risk factors, kidney disease, subclinical cardiovascular disease (CVD), and clinical CVD. We evaluated the association between CKM stage and prevalence and progression of cardiac remodeling and longitudinal risk of incident HF. RESULTS: Of the 5646 participants who had data available for CKM staging (age range, 66 to 90 years; 3271 women [57.9%]), 24 (0.4%) were stage 0 (optimal CKM health), 104 (1.8%) stage 1, 460 (8.1%) stage 2, 3197 (56.0%) stage 3, 1842 (32.3%) stage 4a, and 19 (0.3%) stage 4b. Higher CKM stage was incrementally associated with adverse left ventricular remodeling, worse left ventricular systolic and diastolic function, and greater progression of adverse remodeling by visit 7 (2018–2019). Among participants without prevalent HF at visit 5 (n=4827), the risk of incident HF during follow-up (656 events; median follow-up time, 9.0 years) increased with higher CKM syndrome stage: stage 0/1, 0 events per 1000 person-years; stage 2, 2.9 events/1000 person-years (referent due to no events in stage 0/1); stage 3, 15.1 events/1000 person-years (adjusted hazard ratio, 3.6 [95% CI, 2.1–6.0]); stage 4, 37.4 events/1000 person-years (adjusted hazard ratio, 8.3 [95% CI, 4.9–14.2]; P trend <0.001). CONCLUSIONS: Poor CKM health was widespread among community-dwelling older adults, with higher CKM stage associated with adverse myocardial remodeling and increased risk of incident HF.


  • Open Access

    Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism

    by Weihong Tang, Aixin Li, Thomas R. Austin, Sigrid K. Brækkan, Therese H. Nøst, Xumin Li, Rajat Deo, Ruth Dubin, Peter Ganz, Weihua Guan, et al.

    BACKGROUND: Venous thromboembolism (VTE) is a leading cardiovascular disease, yet its etiology is incompletely understood. This study used large-scale, high-throughput aptamer-based proteomics to identify new circulating protein biomarkers and biological pathways for incident VTE. METHODS: We included 4 longitudinal cohorts (the ARIC study [Atherosclerosis Risk in Communities], CHS [Cardiovascular Health Study], MESA [Multi-Ethnic Study of Atherosclerosis], and the HUNT study [Trøndelag Health]) that identified 1371 incident noncancer VTEs among 20 737 participants followed for a maximum of 10 to 29 years. We used the SomaScan to measure baseline plasma levels of ≈5000 to 7000 proteins and examined the prospective relationships between the protein biomarkers and noncancer VTE. We then conducted an external replication of top VTE proteins in 783 incident noncancer VTEs among 39 097 participants in the UKB study (UK Biobank) based on the Olink proteomics platform. We used Cox proportional hazards regression to estimate the association between each protein biomarker and VTE risk. Mendelian randomization (MR) analysis was used to assess the possible causal associations between identified proteins and VTE risk. RESULTS: There were 23 proteins that exceeded a false discovery rate–adjusted P P -4 ) in the discovery meta-analysis of ARIC, CHS, and MESA and were replicated in HUNT at (unadjusted) P P P <0.05) in VTE risk. The direction of association from the MR analyses was opposite of that from the VTE proteomics analysis for TIMP4 and TIMD4 but was consistent for CST3. CONCLUSIONS: We identified several novel plasma proteins for VTE that reflect biological processes outside established VTE pathophysiology, including extracellular matrix regulation, immunity, immune–vascular endothelium interactions, and vascular senescence. Results may provide new modifiable targets to improve VTE risk stratification, prevention, or treatment.